EA201492010A1 - Применение высокой дозы лахинимода для лечения рассеянного склероза - Google Patents
Применение высокой дозы лахинимода для лечения рассеянного склерозаInfo
- Publication number
- EA201492010A1 EA201492010A1 EA201492010A EA201492010A EA201492010A1 EA 201492010 A1 EA201492010 A1 EA 201492010A1 EA 201492010 A EA201492010 A EA 201492010A EA 201492010 A EA201492010 A EA 201492010A EA 201492010 A1 EA201492010 A1 EA 201492010A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- human patient
- multiple sclerosis
- treating
- pharmaceutically acceptable
- treatment
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 4
- 206010071068 Clinically isolated syndrome Diseases 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024806 Brain atrophy Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641389P | 2012-05-02 | 2012-05-02 | |
| PCT/US2013/039090 WO2013166166A1 (en) | 2012-05-02 | 2013-05-01 | Use of high dose laquinimod for treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201492010A1 true EA201492010A1 (ru) | 2015-06-30 |
Family
ID=49514859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201492010A EA201492010A1 (ru) | 2012-05-02 | 2013-05-01 | Применение высокой дозы лахинимода для лечения рассеянного склероза |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20130303569A1 (enExample) |
| EP (1) | EP2844255A4 (enExample) |
| JP (2) | JP2015515985A (enExample) |
| KR (1) | KR20150013658A (enExample) |
| CN (2) | CN104284663A (enExample) |
| AR (1) | AR090885A1 (enExample) |
| AU (1) | AU2013256352A1 (enExample) |
| BR (1) | BR112014027010A2 (enExample) |
| CA (1) | CA2870684A1 (enExample) |
| CL (1) | CL2014002935A1 (enExample) |
| EA (1) | EA201492010A1 (enExample) |
| HK (1) | HK1206246A1 (enExample) |
| IL (1) | IL235337A0 (enExample) |
| MX (1) | MX2014013039A (enExample) |
| PE (1) | PE20150161A1 (enExample) |
| PH (1) | PH12014502447A1 (enExample) |
| SG (1) | SG11201406594UA (enExample) |
| TW (2) | TW201804997A (enExample) |
| UY (1) | UY34775A (enExample) |
| WO (1) | WO2013166166A1 (enExample) |
| ZA (1) | ZA201408820B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201401330YA (en) | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| MX2014009889A (es) | 2012-02-16 | 2014-11-13 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos. |
| US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| MX2015004564A (es) * | 2012-10-12 | 2015-07-21 | Teva Pharma | Laquinimod para producir el daño talamico en la esclerosis multiple. |
| EA201590788A1 (ru) | 2012-11-07 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Аминные соли лахинимода |
| KR20150119227A (ko) * | 2013-02-15 | 2015-10-23 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료 |
| JP2016514162A (ja) | 2013-03-14 | 2016-05-19 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドナトリウムの結晶およびその製造のための改善された方法 |
| AR098924A1 (es) * | 2013-12-23 | 2016-06-22 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida |
| HK1231413A1 (zh) | 2014-04-29 | 2017-12-22 | Teva Pharmaceutical Industries Ltd. | 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
| WO2017027512A1 (en) * | 2015-08-13 | 2017-02-16 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to treat traumatic brain injury |
| US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
| MX2021000094A (es) * | 2018-07-20 | 2021-03-25 | Merck Patent Gmbh | Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| HRP20160455T1 (hr) * | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| WO2007146331A1 (en) * | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| NZ597378A (en) * | 2009-06-19 | 2014-08-29 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
| WO2011086470A1 (en) * | 2010-01-13 | 2011-07-21 | Ramot At Tel-Aviv University Ltd | Treatment of multiple sclerosis |
| SG11201401330YA (en) * | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| KR20150119227A (ko) * | 2013-02-15 | 2015-10-23 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료 |
-
2013
- 2013-04-29 TW TW106117959A patent/TW201804997A/zh unknown
- 2013-04-29 TW TW102115308A patent/TW201347762A/zh unknown
- 2013-04-29 AR ARP130101459A patent/AR090885A1/es unknown
- 2013-04-30 UY UY0001034775A patent/UY34775A/es not_active Application Discontinuation
- 2013-05-01 US US13/874,537 patent/US20130303569A1/en not_active Abandoned
- 2013-05-01 HK HK15106789.5A patent/HK1206246A1/xx unknown
- 2013-05-01 CA CA2870684A patent/CA2870684A1/en not_active Abandoned
- 2013-05-01 BR BR112014027010A patent/BR112014027010A2/pt not_active IP Right Cessation
- 2013-05-01 CN CN201380022530.XA patent/CN104284663A/zh active Pending
- 2013-05-01 PE PE2014001911A patent/PE20150161A1/es not_active Application Discontinuation
- 2013-05-01 JP JP2015510436A patent/JP2015515985A/ja not_active Withdrawn
- 2013-05-01 CN CN201610240473.8A patent/CN105832733A/zh active Pending
- 2013-05-01 EP EP13784231.6A patent/EP2844255A4/en not_active Withdrawn
- 2013-05-01 EA EA201492010A patent/EA201492010A1/ru unknown
- 2013-05-01 MX MX2014013039A patent/MX2014013039A/es unknown
- 2013-05-01 AU AU2013256352A patent/AU2013256352A1/en not_active Abandoned
- 2013-05-01 KR KR1020147033707A patent/KR20150013658A/ko not_active Withdrawn
- 2013-05-01 WO PCT/US2013/039090 patent/WO2013166166A1/en not_active Ceased
- 2013-05-01 SG SG11201406594UA patent/SG11201406594UA/en unknown
-
2014
- 2014-10-26 IL IL235337A patent/IL235337A0/en unknown
- 2014-10-29 CL CL2014002935A patent/CL2014002935A1/es unknown
- 2014-10-31 PH PH12014502447A patent/PH12014502447A1/en unknown
- 2014-12-02 ZA ZA2014/08820A patent/ZA201408820B/en unknown
-
2015
- 2015-06-05 US US14/731,971 patent/US20150265592A1/en not_active Abandoned
- 2015-09-15 US US14/854,849 patent/US20160000775A1/en not_active Abandoned
-
2017
- 2017-07-21 JP JP2017141409A patent/JP2017222691A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CL2014002935A1 (es) | 2015-03-06 |
| AU2013256352A1 (en) | 2014-11-27 |
| TW201347762A (zh) | 2013-12-01 |
| MX2014013039A (es) | 2015-02-04 |
| PE20150161A1 (es) | 2015-02-22 |
| SG11201406594UA (en) | 2014-11-27 |
| KR20150013658A (ko) | 2015-02-05 |
| ZA201408820B (en) | 2016-06-29 |
| US20150265592A1 (en) | 2015-09-24 |
| EP2844255A1 (en) | 2015-03-11 |
| US20160000775A1 (en) | 2016-01-07 |
| AR090885A1 (es) | 2014-12-10 |
| US20130303569A1 (en) | 2013-11-14 |
| TW201804997A (zh) | 2018-02-16 |
| CN105832733A (zh) | 2016-08-10 |
| WO2013166166A1 (en) | 2013-11-07 |
| PH12014502447A1 (en) | 2015-01-12 |
| HK1206246A1 (en) | 2016-01-08 |
| UY34775A (es) | 2013-11-29 |
| CN104284663A (zh) | 2015-01-14 |
| JP2017222691A (ja) | 2017-12-21 |
| CA2870684A1 (en) | 2013-11-07 |
| JP2015515985A (ja) | 2015-06-04 |
| IL235337A0 (en) | 2014-12-31 |
| BR112014027010A2 (pt) | 2017-06-27 |
| EP2844255A4 (en) | 2015-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| EA201270041A1 (ru) | Лечение рассеянного склероза лаквинимодом | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| JP2015515985A5 (enExample) | ||
| EA201270205A1 (ru) | Фармацевтические композиции для лечения рака и других заболеваний и нарушений состояния здоровья | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| TW201129361A (en) | Methods for treating pain | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| DK2091520T3 (da) | Oral doseringsform omfattende trisubstituerede glycerol-forbindelser | |
| MX2014011843A (es) | Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma. | |
| MX2010006310A (es) | O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor. | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| RU2012114097A (ru) | Терапевтический агент против хронической боли | |
| HK1225969A1 (zh) | 利用低剂量的拉喹莫德治疗克隆氏病 | |
| RU2023102211A (ru) | Схемы дозирования иммуноконъюгата anti-folr1 |